Department of Microbiology, All India Institute of Medical Sciences, New Delhi, India.
Department of Microbiology, All India Institute of Medical Sciences, New Delhi, India
Antimicrob Agents Chemother. 2018 Jul 27;62(8). doi: 10.1128/AAC.02264-17. Print 2018 Aug.
This prospective study shows that the rate of azole-resistant (ARAF) in an immunocompromised Indian patient population with invasive aspergillosis (IA) is low, 6/706 (0.8%). This low rate supports the continued use of voriconazole as the first line of treatment. However, the ARAF isolates from India in this study exhibited three kinds of unreported mutations, of which two were at hot spots, G54R and P216L, while one was at codon Y431C.
这项前瞻性研究表明，在患有侵袭性曲霉病（IA）的免疫功能低下的印度患者人群中，唑类耐药（ARAF）的发生率较低，为 6/706（0.8%）。这一低发生率支持继续将伏立康唑作为一线治疗药物。然而，本研究中来自印度的 ARAF 分离株表现出三种未报道的突变，其中两种位于热点，G54R 和 P216L，而另一种位于 Y431C 密码子。
